14,900 Eton Pharmaceuticals, Inc. $ETON Shares Sold by Sigma Planning Corp

Sigma Planning Corp cut its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 49.7% during the 3rd quarter, Holdings Channel reports. The firm owned 15,100 shares of the company’s stock after selling 14,900 shares during the quarter. Sigma Planning Corp’s holdings in Eton Pharmaceuticals were worth $777,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ETON. BlackRock Inc. bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth approximately $68,629,000. Nantahala Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at $42,569,426. Pillsbury Lake Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth $14,015,083. Panoramic Capital LLC purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth about $7,537,000. Finally, Cannell Capital LLC bought a new position in Eton Pharmaceuticals during the second quarter valued at about $6,181,041. 27.86% of the stock is owned by institutional investors.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 79,166 shares of company stock valued at $4,809,672. Insiders own 16.49% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $52.18 on Friday. Eton Pharmaceuticals, Inc. has a 52-week low of $14.27 and a 52-week high of $66.37. The stock’s 50-day simple moving average is $56.00 and its 200 day simple moving average is $35.57. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 137.32 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The firm had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Research analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ETON shares. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday, October 14th. B. Riley Financial reissued a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Craig Hallum reissued a “buy” rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Finally, Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $71.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.